Single dose use of CD20-specific binding molecules

Details for Australian Patent Application No. 2006272597 (hide)

Owner Trubion Pharmaceuticals

Inventors Bruge, Daniel Jonathan

Agent Wrays

Pub. Number AU-A-2006272597

PCT Pub. Number WO2007/014238

Priority 60/702,498 25.07.05 US; 60/702,875 27.07.05 US

Filing date 25 July 2006

Wipo publication date 1 February 2007

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 31/00 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

7 February 2008 PCT application entered the National Phase

  PCT publication WO2007/014238 Priority application(s): WO2007/014238

21 April 2011 Assignment before Grant

  Trubion Pharmaceuticals, Inc. The application has been assigned to Emergent Product Development Seattle LLC

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006272609-Abl kinase inhibition

2006272596-Radioprotective agents